drugset / Trial / NCT01913353
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
Phase 3
Completed
440 enrolled
Bavarian Nordic
US Army Medical Research Institute of Infectious Diseases · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
To demonstrate the efficacy of MVA-BN® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody response and by showing that vaccination prior to administration of ACAM2000® results in an attenuated take.
Timeline
- Start
- 2015-03
- Primary completion
- 2017-03
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACAM2000 | Vaccine | 0.0025 ml | Other |
| Subject | IMVAMUNE | Vaccine | 0.5 ml | Subcutaneous |
Indications
No indication recorded.